Iron Fortification Trail Using NaFeEDTA in Iron Deficient Lead-exposed Children

May 9, 2014 updated by: Prof. Michael B. Zimmermann, Swiss Federal Institute of Technology

Interactions of Lead Intoxication and Iron Deficiency in Morocco: The Effects of Iron Fortification With and Without NaEDTA on Lead Burden, Iron Status and Cognition in Children

In a cross-sectional study allotted by the ethical committee of the ETH Zurich, we are investigating the extent of anemia, iron deficiency and lead intoxication in young children. For this purpose an assessment of body lead burden and iron status was conducted in a cohort of individuals residing in areas of presumed high lead exposure. Associations between lead burden and iron status will be investigated in the near future (current status of the study).

In a follow-on intervention study, the effect of iron fortification with and without NaEDTA on blood lead levels in lead-exposed children will be evaluated; and the relative impact of these two strategies on child growth, motor and cognitive test performance will be compared.

This study will investigate the potential use of iron fortification to not only combat anemia but also reduce body lead burden in lead-exposed populations; it specifically investigates whether iron fortification with NaFeEDTA could have additional beneficial effects to iron alone.

Study Overview

Detailed Description

Introduction Coexisting chronic lead poisoning and iron deficiency anemia (IDA) are common in urban areas in developing regions, particularly in young children. In urban Morocco, anemia affects more than 1/3rd of schoolchildren and lead exposure is high. Lead poisoning and IDA both impair cognitive development and educability and may therefore have substantial health, social and economic costs on developing countries.

Iron status alters susceptibility to gastrointestinal lead exposure; absorption of lead is sharply increased in children with IDA. IDA upregulates the divalent metal transporter trans-port protein (DMT-1) and increases lead absorption. Thus, iron fortification to reduce IDA may also reduce lead absorption and be an effective strategy to accompany environmental lead abatement. The optimal iron compound for wheat flour is currently debated, and although elemental iron compounds are commonly used, they may be only poorly absorbed in the face of inhibitory compounds found in wheat flour.

A form of chelated iron, NaFeEDTA, is a promising iron fortificant that is recommended for wheat flour fortification. It is also a lead chelator. It may be superior to other iron fortificants in its ability to reduce body lead burden, due to:

  1. its iron is highly bioavailable in the face of dietary inhibitors (such as phytic acid in wheat flour); and
  2. potentially, its ability to chelate lead in the gut and bloodstream. Thus, it may be a good choice for fortification of wheat flour in Morocco, particularly in urban areas, to both reduce IDA and lower body lead.

Study aims and objectives:

  1. Assessment of body lead burden and iron status in a cohort of individuals residing in areas of presumed high lead exposure. Investigation of associations between lead burden and iron status.
  2. Comparison of effect of iron fortification with and without NaEDTA on body lead and iron status in lead-exposed children; and the relative impact on cognition.

Study hypotheses:

The prevalence of iron deficiency and elevated blood lead will be high in children in this region.

2) Body lead burden, as assessed by blood lead levels and urinary lead and delta-aminolevulinic acid (ALA), will be higher in individuals with poorer iron status.

3) Poor iron status will be associated with low intakes of bioavailable iron. 4) Greater severity of iron deficiency and/or higher body lead in children will predict poorer performance on cognitive and motor tests, and these conditions will interact to predict poorer performance.

Study design:

Our studies will be carried out in one of the four sub-economic areas, that were previously used in the baseline assessment in and near Marrakesh, Morocco (exact site still needs to be determined according to extend of lead contamination on the level of human population). Body lead burden and iron status will be determined, and associations between these examined using a cross-sectional design. For this purpose, blood and urine samples will be collected from two groups (preschool and school-aged children), residing in an area of high lead exposure.

Study design:

An 8-month intervention study in iron deficient, lead-exposed school children (n=500) will be designed to investigate whether iron fortification to reduce IDA may also reduce lead absorption and be an effective strategy to accompany environmental lead abatement.

For this purpose these children will be divided into four groups to receive a daily fortified baked snack containing either: 1) 66.4 mg NaFeEDTA ; 2) 52.2 mg Na2EDTA dehydrate; 3) 27.1 mg FeSO4 ; or 4) no fortificants.

Study Type

Interventional

Enrollment (Actual)

457

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Zurich, Switzerland, 8092
        • Swiss federal institute of Technology (ETH)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 11 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • school and preschool children living in a lead-exposed environment with a high prevalence of iron deficiency

Exclusion Criteria:

  • chronic or severe illnesses
  • history of bleeding disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: NaFeEDTA treatment, biscuit
Group receives 10 mg of Fe in form of NaFeEDTA per day. wheat flour based biscuit
10 mg of iron per day for 8 months, either in the form of NaFeEDTA
10 mg of iron per day for 8 months, in the form of FeSo4
EDTA fortified biscuit on a daily basis for 8 months
control biscuit on a daily basis for 8 months
Active Comparator: EDTA treatment, biscuit
Group receives Na2EDTA enriched biscuit
10 mg of iron per day for 8 months, either in the form of NaFeEDTA
10 mg of iron per day for 8 months, in the form of FeSo4
EDTA fortified biscuit on a daily basis for 8 months
control biscuit on a daily basis for 8 months
Active Comparator: FeSO4 treatment, biscuit
Group receives 10 mg of iron as FeSo4 per day for 8 months
10 mg of iron per day for 8 months, either in the form of NaFeEDTA
10 mg of iron per day for 8 months, in the form of FeSo4
EDTA fortified biscuit on a daily basis for 8 months
control biscuit on a daily basis for 8 months
Placebo Comparator: control treatment, biscuit
group receives a biscuit without additional iron
10 mg of iron per day for 8 months, either in the form of NaFeEDTA
10 mg of iron per day for 8 months, in the form of FeSo4
EDTA fortified biscuit on a daily basis for 8 months
control biscuit on a daily basis for 8 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
body lead burden
Time Frame: 8 months
changes in blood lead levels over time of the intervention
8 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Iron status
Time Frame: 8 months
changes in iron status (SF,Hb, TfR) before and after intervention
8 months
cognitive development
Time Frame: 8 months
changes in cognitive development (using the K ABC II) before and after intervention
8 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Michael B Zimmermann, Prof. Dr. med, Swiss federal institute of Technology (ETH)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2011

Primary Completion (Actual)

June 1, 2012

Study Completion (Actual)

June 1, 2012

Study Registration Dates

First Submitted

November 8, 2011

First Submitted That Met QC Criteria

April 4, 2012

First Posted (Estimate)

April 6, 2012

Study Record Updates

Last Update Posted (Estimate)

May 12, 2014

Last Update Submitted That Met QC Criteria

May 9, 2014

Last Verified

May 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Iron Deficiency

Clinical Trials on iron fortified biscuits

3
Subscribe